Geretti AM - Search Results

1

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database; UK CHIC study. Mackie NE, et al. Among authors: geretti am. AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179. AIDS. 2013. PMID: 24157905

2

Prevalence of antiretroviral resistance in a South London cohort of treatment-naive HIV-1-infected patients.

Geretti AM, Smith M, Osner N, O'Shea S, Chrystie I, Easterbrook P, Zuckerman M. Geretti AM, et al. AIDS. 2001 May 25;15(8):1082-4. doi: 10.1097/00002030-200105250-00028. AIDS. 2001. PMID: 11400002 No abstract available.

3

Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1.

Geretti AM, Smith M, Watson C, Mullen J, Osner N, O'Shea S, Chrystie I, Zuckerman M, Easterbrook P. Geretti AM, et al. AIDS. 2002 Nov 22;16(17):2358-60. doi: 10.1097/00002030-200211220-00026. AIDS. 2002. PMID: 12441818 No abstract available.

4

Essential benefits of nucleoside analogue regimens in failing therapy.

Geretti AM. Geretti AM. J HIV Ther. 2004 May;9(2):28-33. J HIV Ther. 2004. PMID: 15238873 Review.

5

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. Among authors: geretti am. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854

6

Human T-cell lymphotropic virus antibody prevalence in HIV-1-infected individuals attending a sexual health clinic in South-East London.

Cooke FJ, Geretti AM, Zuckerman M. Cooke FJ, et al. Among authors: geretti am. J Med Virol. 2005 Jun;76(2):143-5. doi: 10.1002/jmv.20336. J Med Virol. 2005. PMID: 15834880

7

The clinical significance of viral fitness.

Geretti AM. Geretti AM. J HIV Ther. 2005 Mar;10(1):6-10. J HIV Ther. 2005. PMID: 15951728 Review.

8

High levels of discordance between sequencing and serological subtyping in a predominantly non-B subtype HIV-1 infected cohort.

Smith M, Geretti AM, Osner N, Easterbrook P, Zuckerman M. Smith M, et al. Among authors: geretti am. J Clin Virol. 2005 Aug;33(4):312-8. doi: 10.1016/j.jcv.2004.08.020. Epub 2005 Jan 19. J Clin Virol. 2005. PMID: 16036181

9

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.

Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M; UK Group on Transmitted HIV Drug Resistance. Cane P, et al. Among authors: geretti am. BMJ. 2005 Dec 10;331(7529):1368. doi: 10.1136/bmj.38665.534595.55. Epub 2005 Nov 18. BMJ. 2005. PMID: 16299012 Free PMC article.

10

HIV-1 subtypes: epidemiology and significance for HIV management.

Geretti AM. Geretti AM. Curr Opin Infect Dis. 2006 Feb;19(1):1-7. doi: 10.1097/01.qco.0000200293.45532.68. Curr Opin Infect Dis. 2006. PMID: 16374210 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters